Examkin

Soru

Zorluk: Çok zorMonitoring and Treatment Evaluation

A 60-year-old woman is evaluated in the intensive care unit on day 10 of her hospitalization. She was initially admitted for an acute submassive pulmonary embolism and started on a continuous intravenous unfractionated heparin infusion. On hospital day 6, her platelet count dropped abruptly from a baseline of 240,000/mm³ to 70,000/mm³. Heparin-induced thrombocytopenia (HIT) was suspected; heparin was immediately discontinued, and a continuous intravenous infusion of argatroban was initiated. Subsequent enzyme-linked immunosorbent assay (ELISA) and serotonin release assay (SRA) confirmed the diagnosis of HIT.

Laboratory results over the last few days are as follows:

Hospital DayPlatelet CountaPTT (sec)
Day 670,000/mm³45
Day 8110,000/mm³65
Day 10165,000/mm³68

The patient is clinically stable with no signs of active bleeding or recurrent thrombosis. The care team plans to transition her to oral warfarin for long-term anticoagulation. Which of the following is the most appropriate protocol for monitoring and evaluating this patient's transition to oral warfarin therapy?

  1. A
    Initiate warfarin concurrently, overlap for at least 5 days, and discontinue argatroban when the INR reaches a target of 2.0 to 3.0.
  2. B
    Discontinue argatroban, wait 4 to 6 hours for drug clearance, and then initiate warfarin to avoid additive bleeding risk.
  3. C
    Initiate warfarin concurrently, and discontinue argatroban immediately, monitoring the INR daily until it is therapeutic.
  4. D
    Initiate warfarin concurrently, and transition from argatroban to subcutaneous enoxaparin to serve as the bridge until the INR is therapeutic.
  5. Initiate warfarin concurrently, discontinue argatroban when the combined INR exceeds 4.0, and recheck the INR in 4 to 6 hours.Cevap

Cevap

Initiate warfarin concurrently, discontinue argatroban when the combined INR exceeds 4.0, and recheck the INR in 4 to 6 hours.
The correct answer identifies the standard, guideline-based protocol for bridging argatroban to warfarin. Argatroban is a direct thrombin inhibitor that interferes with the prothrombin time (PT) assay, artificially elevating the INR. Therefore, when both drugs are co-administered, a target INR of 2.0 to 3.0 is inadequate because it reflects the combined effect, not the warfarin effect alone. Guidelines recommend co-administering both drugs until the combined INR is > 4.0. At that point, argatroban is held, and because it has a short half-life (~45 minutes in patients with normal hepatic function), rechecking the INR in 4 to 6 hours provides an accurate measurement of the true, warfarin-induced INR. If this repeat INR is in the therapeutic range (2.0 to 3.0), argatroban can be permanently discontinued.

Adım Adım Çözüm

1
Evaluate the patient's readiness to transition to warfarin.
The patient's platelet count has recovered to >150,000/mm³ (currently 165,000/mm³), which is the standard threshold for safely initiating warfarin in a patient with HIT.
Starting warfarin before platelet recovery in HIT can increase the risk of venous limb gangrene and microthrombosis.
2
Analyze the pharmacokinetic interaction between argatroban and the INR laboratory assay.
Argatroban is a direct thrombin inhibitor that artificially prolongs the prothrombin time (PT), leading to a falsely elevated INR.
Understanding this lab interference is critical to prevent premature discontinuation of the parenteral anticoagulant.
3
Select the correct bridging protocol based on established guidelines for argatroban-to-warfarin transition.
The protocol requires co-administering both drugs until the combined, artificially elevated INR is >4.0.
An INR of 2.0 to 3.0 on combined therapy would reflect a subtherapeutic true warfarin level.
4
Determine the appropriate follow-up monitoring step after stopping argatroban.
Stop the argatroban infusion and recheck the INR in 4 to 6 hours.
Argatroban has a short half-life (~45 minutes). Rechecking the INR after 4-6 hours allows the drug to clear, revealing the accurate, true INR produced solely by warfarin, which should be in the target 2.0-3.0 range.

Anahtar Kavram

Patients transitioning from argatroban to warfarin must have overlapping therapy until the combined INR is >4.0 due to argatroban's artificial elevation of the prothrombin time; the true INR must be verified 4-6 hours after stopping argatroban.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru